PBM Rebating Practices: How Much Do Employer Plan Sponsors Really Know?

A National Pharmaceutical Council survey of self-insured employers offers a new perspective on pharmacy benefit manager claims that rebating practices only reflect the decisions made by their clients.

Employers May Need To Rethink Their Approach To PBM Contracting. • Source: Shutterstock

Nearly two-thirds (62.7%) of employers with self-funded pharmacy benefits reported agreements for specialty drugs that include a guaranteed total rebate amount over the course of a contract, according to a national survey by National Pharmaceutical Council researchers.

Key Takeaways
  • Almost 63% of employers offering self-insured pharmacy benefits choose guaranteed rebates in their vendor contracts with PBMs, according to a survey by the National Pharmaceutical Council.

    ...

Not surprisingly, employers with rebate guarantees “ascribed a higher level of importance” to guarantees in the PBM bidding process than employers receiving rebates without a guarantee and those who do...

More from Market Access

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By 

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.